Acura Pharmaceuticals, Inc.
) recently gave an update on its next generation pseudoephedrine
hydrochloride tablet, Nexafed, which was launched in Dec
Nexafed (30mg) is an immediate-release, next generation
pseudoephedrine tablet which combines effective nasal congestion
relief with IMPEDE technology that disrupts the conversion of
pseudoephedrine into the dangerous drug, methamphetamine. The
drug also meets a key human clinical efficacy standard of the
U.S. Food and Drug Administration (FDA).
As per the 2011 National Survey on Drug Use and Health,
roughly 439,000 Americans (≥ 12 years) had abused
The company reported that Nexafed is currently being sold in
more than 2,600 U.S. pharmacies and has become the standard of
care in many of these pharmacies. Repeat orders from pharmacies
have also increased.
As on Aug 2013, Nexafed was distributed in about 1,400 U.S.
pharmacies, of which about 66.7% were repeat customers. During
the quarter and six months ended Jun 30, 2013, Acura shipped
approximately $25,000 and $58,000 worth of Nexafed,
We are encouraged by the expansion in the distribution network
of Nexafed. Nexafed is Acura's second product to enter the
market. Acura has initiated research on Impede 2.0, the next
generation IMPEDE Technology, to upgrade Nexafed.
Acura has produced pilot scale quantities of Nexafed with
IMPEDE 2.0 technology for further meth-resistance testing and
pharmacokinetic testing. After successful testing, Acura will
commercially introduce Nexafed using IMPEDE 2.0 technology.
Acura currently carries a Zacks Rank #3 (Hold). Other
companies that look well-positioned include
Questcor Pharmaceuticals Inc.
Actelion Ltd. (
). While Questcor is a Zacks Rank #1 (Strong Buy) stock, Actavis
and Actelion are Zacks Rank #2 (Buy) stocks.
ACTAVIS INC (ACT): Free Stock Analysis Report
ACURA PHARMACT (ACUR): Get Free Report
ACTELION LTD (ALIOF): Get Free Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis
To read this article on Zacks.com click here.